From: Fast Company Compass - Monday Nov 23, 2020 02:25 pm
Fast Company Compass
The announcement of a new COVID-19 vaccine from Oxford University—the third such breakthrough in as many weeks—is reason to celebrate. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
Presented by
The announcement of a new COVID-19 vaccine from Oxford University—the third such breakthrough in as many weeks—is reason to celebrate. While the Oxford vaccine is reported to have a 70% efficacy rating, scientists believe they can boost that number with some tinkering. Perhaps most important, Oxford’s vaccine looks to price in the $4 per dose range—a fraction of the cost of similar vaccines from Pfizer and Moderna.

Yet as Adele Peters reports, life may not go back to normal for some time. Even after you’ve been vaccinated, if you’re lucky enough to get a vaccine in the months that follow the initial rollout, you’ll still have to wear masks and practice social distancing. Pfizer’s study showed that its vaccine has 95% efficacy. But there’s still a risk: Scientists don’t yet have all of the necessary data to know exactly what it’s effective at preventing. Read more here.
Sorry, the COVID-19 vaccine won’t make life go back to normal right away

If you were hoping that the new COVID-19 vaccines could make it possible to stop wearing masks and social distancing, think again.

Oxford COVID vaccine: Not as effective, but better in 2 big ways

The effacacy of the Oxford vaccine is relatively low compared to Moderna’s and Pfizer’s, but it has two major advantages over its competitors.
Black Friday is notorious for terrible impulse buys. What if we just skipped it this year?

The pandemic has forced many of us to shop more consciously. Can we keep it up?

a message from LUCIDspark
Building Your Company’s Future through Visual Collaboration
With the sudden shift to remote work, office environments changed from cubicles and meeting rooms to kitchen tables and bedrooms. Finding avenues for collaboration in this "new normal" is a huge challenge for dispersed teams. Here’s the secret that can help you jump-start creativity again. 
These solar panels don’t need the sun to produce energy

Cloudy days pose a real problem for solar panels. But a new innovation can convert UV light to energy—even if the sun isn’t shining. Read more.

Jeff Bezos: Here’s how I make Amazon’s highest-stakes decisions

In an excerpt from a new collection of his writings, Amazon’s CEO says that his secret is making fewer, better decisions—and thinking three years out.

remote work
3 tricks for dealing with annoying coworkers remotely

You would think that working remotely would make bothersome colleagues less bothersome, but that’s not the case.

work life
These are the interview questions candidates hate the most

In a recent survey, people ranked these questions as the worst to answer during an interview.

Away’s new holiday luggage collection is designed for our stay-at-home era

Travel has changed during the pandemic. Away’s latest collection works for when you’re staying close to home—and will come in handy after the pandemic, too.

The frustrating reason why your therapist may have to break up with you

Laws that dictate where therapists can practice were put on hold during the pandemic, allowing for an explosion of teletherapy. But with rules changing, mental health practitioners are wary that they may lose their licenses.

Oxford announces COVID-19 vaccine: Here’s what to know
Another week and more good news in the fight against COVID-19, this time from Oxford University in the United Kingdom. The Oxford vaccine has a major drawback that the American vaccines don’t, but it also has some key advantages.
The Oxford vaccine only has a 70% efficacy rating, but it could increase: That efficacy rating is not as good as the vaccines from Pfizer (95% efficacy) and Moderna (94.5% efficacy). However, a smaller trial within the main trial showed that people who received a half first dose followed by a subsequent full dose had a 90% chance of being inoculated from the virus.
The Oxford vaccine is far cheaper: While Pfizer’s vaccine costs about $20 per dose and Moderna’s vaccine costs about $34 per dose, Oxford’s vaccine is only about $4 per dose. This could make the Oxford vaccine the better option to inoculate poorer, developing countries. Pharma giant AstraZeneca says it will make three billion doses for the world next year.
The Oxford vaccine doesn’t require extreme cold storage: This is perhaps the biggest advantage the Oxford vaccine has. While the Pfizer vaccine needs to be stored at -94°F, and Moderna’s needs to be stored at -4°F during shipping, the Oxford vaccine requires only standard refrigeration.
Office 365 All-in-One for Dummies
The deepest reference on Microsoft’s productivity service. Click here to download your free e-book.
What do you think of this newsletter?
Tell us here.
You can update your details here.
If you don’t want to receive Compass anymore, unsubscribe here
If you were forwarded Compass and like it, subscribe here

View this newsletter online

7 World Trade Center, 29th Floor, New York, NY 10007-2195